Home › Companies › Teva Pharmaceutical Industries Limited › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Teva Pharmaceutical Industries Limited’s Form 8-K, filed May 28, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 28, 2026: 3 items on Teva Pharmaceutical Industries Limited’s Form 8-K, filed May 28, 2026: 2 approved · 1 passed (calculated).
Significant dissent: 1 director (28.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Teva Pharmaceutical Industries Limited in the interactive database Compare manager voting policies
These tallies are Teva Pharmaceutical Industries Limited’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Sol J. Barer | 627,816,662 | 245,921,571 | 530,682 | -- | 50,661,570 | 72% | Passed (calculated) | — |
| 2. On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting | 795,976,042 | 77,082,847 | 1,170,026 | -- | 50,661,570 | 91% | Approved | — |
| 3. The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2027 annual meeting of shareholders | 880,542,242 | 36,085,507 | 525,382 | -- | 0 | 96% | Approved | — |
Source: Teva Pharmaceutical Industries Limited, Form 8-K, filed with the SEC on May 28, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
620 asset managers disclosed a vote on at least one Teva Pharmaceutical Industries Limited item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Teva Pharmaceutical Industries Limited’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Description as filed by funds: To appoint Dr. Sol J. Barer to serve as a director until Teva's 2029 Annual Meeting of Shareholders
Teva Pharmaceutical Industries Limited’s own tally for this item (“Elect Director: Dr. Sol J. Barer”): 627,816,662 for, 245,921,571 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 110 asset managers below reported 155,718,632 for, 2,045,492 against, 59,891 abstained, 336,890 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 31,361,106 | 0 | 0 | 0 | For |
| Vanguard | 31,267,716 | 0 | 0 | 0 | For |
| BlackRock | 27,277,644 | 0 | 0 | 0 | For |
| Investment Managers Series Trust | 13,399,660 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 5,843,812 | 0 | 0 | 0 | For |
| Capital Group | 5,011,035 | 0 | 0 | 0 | For |
| Charles Schwab | 4,414,989 | 0 | 0 | 0 | For |
| TIAA | 2,550,548 | 0 | 0 | 0 | For |
| Jackson National | 2,511,684 | 16,909 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 2,446,446 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,353,527 | 0 | 0 | 0 | For |
| Lord Abbett | 2,232,424 | 0 | 0 | 0 | For |
| Hartford | 2,050,890 | 0 | 0 | 0 | For |
| State Street | 2,047,360 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,036,647 | 0 | 0 | 0 | For |
| Invesco | 1,876,080 | 0 | 0 | 0 | For |
| Victory Capital | 1,767,838 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 1,448,890 | 0 | 0 | 0 | For |
| SOUND SHORE FUND INC | 1,269,505 | 0 | 0 | 0 | For |
| First Trust | 1,160,521 | 0 | 0 | 0 | For |
| Prudential/PGIM | 996,900 | 0 | 0 | 0 | For |
| Allspring | 907,121 | 0 | 0 | 0 | For |
| Dimensional | 0 | 892,174 | 0 | 0 | Against |
| DWS | 615,337 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 574,218 | 0 | 0 | 0 | For |
Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).
Combines 24 wordings of this item as funds reported it.
91% Approved · of votes cast
Prior year: 87.4% for (June 5, 2025 meeting) ▲ 3.8 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERS
Teva Pharmaceutical Industries Limited’s own tally for this item (“2. On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting”): 795,976,042 for, 77,082,847 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 31,361,106 | 0 | 0 | 0 | For |
| Vanguard | 31,267,716 | 0 | 0 | 0 | For |
| BlackRock | 27,277,644 | 0 | 0 | 0 | For |
| Investment Managers Series Trust | 13,399,660 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 5,843,812 | 0 | 0 | 0 | For |
| Capital Group | 5,011,035 | 0 | 0 | 0 | For |
| Charles Schwab | 4,414,989 | 0 | 0 | 0 | For |
| TIAA | 2,550,548 | 0 | 0 | 0 | For |
| Jackson National | 2,528,593 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 2,446,446 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,353,527 | 0 | 0 | 0 | For |
| Lord Abbett | 2,232,424 | 0 | 0 | 0 | For |
| Hartford | 2,050,890 | 0 | 0 | 0 | For |
| State Street | 2,047,360 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,036,647 | 0 | 0 | 0 | For |
| Invesco | 1,876,080 | 0 | 0 | 0 | For |
| Victory Capital | 1,767,838 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 1,448,890 | 0 | 0 | 0 | For |
| SOUND SHORE FUND INC | 1,269,505 | 0 | 0 | 0 | For |
| First Trust | 1,160,521 | 0 | 0 | 0 | For |
| Prudential/PGIM | 996,900 | 0 | 0 | 0 | For |
| Allspring | 907,121 | 0 | 0 | 0 | For |
| Dimensional | 892,174 | 0 | 0 | 0 | For |
| DWS | 615,337 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 574,218 | 0 | 0 | 0 | For |
Fund voting reports, all 104 managers: 157,511,409 for, 11,884 against, 59,891 abstained, 336,890 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Harel Insurance Investments & Financial Services Ltd. | 77,246,886 | 0 | 0 | 0 | For |
| Migdal Insurance & Financial Holdings Ltd. | 60,694,120 | 0 | 0 | 0 | For |
| Phoenix Financial Ltd. | 54,504,019 | 0 | 0 | 0 | For |
| MENORA MIVTACHIM HOLDINGS LTD. | 53,937,202 | 0 | 0 | 0 | For |
| BlackRock | 42,982,241 | 0 | 0 | 0 | For |
| WCM INVESTMENT MANAGEMENT, LLC | 39,330,516 | 0 | 0 | 0 | For |
| Clal Insurance Enterprises Holdings Ltd | 37,718,089 | 0 | 0 | 0 | For |
| Fidelity | 33,312,389 | 0 | 0 | 0 | For |
| State Street | 15,854,197 | 58,957 | 0 | 0 | For |
| Vanguard | 12,682,712 | 0 | 0 | 0 | For |
| Capital Group | 11,674,171 | 0 | 0 | 0 | For |
| Altshuler Shaham Ltd | 0 | 11,463,884 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 10,605,632 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 10,209,344 | 0 | 0 | 0 | For |
| Janus Henderson | 9,449,845 | 0 | 0 | 0 | For |
| Y.D. More Investments Ltd | 0 | 8,426,222 | 0 | 0 | Against |
| Northern Trust | 6,591,426 | 0 | 0 | 0 | For |
| GLENVIEW CAPITAL MANAGEMENT, LLC | 6,148,015 | 0 | 0 | 0 | For |
| Wellington | 5,658,324 | 0 | 0 | 0 | For |
| Invesco | 5,431,147 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 63,840 | 4,990,570 | 0 | 0 | Against |
| Charles Schwab | 4,620,851 | 0 | 0 | 0 | For |
| ION Fund Management Ltd | 3,883,183 | 0 | 0 | 0 | For |
| AustralianSuper Pty Ltd | 0 | 3,793,078 | 0 | 0 | Against |
| Alyeska Investment Group, L.P. | 3,773,343 | 0 | 0 | 0 | For |
Institutional-manager reports, all 542 managers: 601,844,436 for, 41,765,418 against, 352,705 abstained, 28,591 not voted, 585,954 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2027 ANNUAL MEETING OF SHAREHOLDERS
Teva Pharmaceutical Industries Limited’s own tally for this item (“3. The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2027 annual meeting of shareholders”): 880,542,242 for, 36,085,507 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2027 annual meeting of shareholders, as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 108 asset managers below reported 156,015,752 for, 809,305 against, 59,891 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 31,361,106 | 0 | 0 | 0 | For |
| Vanguard | 31,267,716 | 0 | 0 | 0 | For |
| BlackRock | 27,277,644 | 0 | 0 | 0 | For |
| Investment Managers Series Trust | 13,399,660 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 5,843,812 | 0 | 0 | 0 | For |
| Capital Group | 5,011,035 | 0 | 0 | 0 | For |
| Charles Schwab | 4,414,989 | 0 | 0 | 0 | For |
| TIAA | 2,550,548 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 2,446,446 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,353,527 | 0 | 0 | 0 | For |
| Jackson National | 2,333,740 | 0 | 0 | 0 | For |
| Lord Abbett | 2,232,424 | 0 | 0 | 0 | For |
| Hartford | 2,049,659 | 1,231 | 0 | 0 | For |
| State Street | 2,047,360 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,036,647 | 0 | 0 | 0 | For |
| Invesco | 1,876,080 | 0 | 0 | 0 | For |
| Victory Capital | 1,767,838 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 1,448,890 | 0 | 0 | 0 | For |
| SOUND SHORE FUND INC | 1,269,505 | 0 | 0 | 0 | For |
| First Trust | 1,160,521 | 0 | 0 | 0 | For |
| Prudential/PGIM | 996,900 | 0 | 0 | 0 | For |
| Allspring | 907,121 | 0 | 0 | 0 | For |
| Dimensional | 892,174 | 0 | 0 | 0 | For |
| DWS | 615,337 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 574,218 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).
100% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 0 | 0 | 0 | 0 | Not Voted |
| Empower | 209,104 | 0 | 0 | 0 | For |
Fund voting reports, all 2 managers: 209,104 for, 336,890 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Dorsey Wright & Associates | 240,674 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 240,674 for.
100% of fund votes cast · no official result
Description as filed by funds: RATIFY KESSELMAN AND KESSELMAN AS AUDITORS
The 3 asset managers below reported 489,289 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Tidal Trust IV | 216,116 | 0 | 0 | 0 | For |
| Jackson National | 194,853 | 0 | 0 | 0 | For |
| John Hancock | 78,320 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,164,426,972 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 2.69% |
| 2 | Vanguard | 2.69% |
| 3 | BlackRock | 2.34% |
| 4 | Investment Managers Series Trust | 1.15% |
| 5 | NEW ECONOMY FUND | 0.50% |
| 6 | Capital Group | 0.43% |
| 7 | Charles Schwab | 0.38% |
| 8 | TIAA | 0.22% |
| 9 | Jackson National | 0.22% |
| 10 | OLD WESTBURY FUNDS INC | 0.21% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Harel Insurance Investments & Financial Services Ltd. | 6.63% |
| 2 | Migdal Insurance & Financial Holdings Ltd. | 5.21% |
| 3 | Phoenix Financial Ltd. | 4.68% |
| 4 | MENORA MIVTACHIM HOLDINGS LTD. | 4.63% |
| 5 | BlackRock | 3.69% |
| 6 | WCM INVESTMENT MANAGEMENT, LLC | 3.38% |
| 7 | Clal Insurance Enterprises Holdings Ltd | 3.24% |
| 8 | Fidelity | 2.86% |
| 9 | State Street | 1.37% |
| 10 | Vanguard | 1.09% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Harel Insurance Investments & Financial Services Ltd | 72,325,555 | 6.21% | Schedule 13G, filed February 9, 2026 |
| BlackRock | 65,136,464 | 5.59% | Form 13F, quarter ended March 31, 2026 |
| Migdal Insurance & Financial Holdings Ltd | 61,689,363 | 5.30% | Schedule 13G, filed February 17, 2026 |
| FMR (Fidelity) | 33,132,795 | 2.85% | Form 13F, quarter ended March 31, 2026 |
| State Street | 17,790,020 | 1.53% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 10,564,988 | 0.91% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 8,444,801 | 0.73% | Form 13F, quarter ended March 31, 2026 |
| Northern Trust | 7,635,688 | 0.66% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 7,251,828 | 0.62% | Form 13F, quarter ended March 31, 2026 |
| JPMorgan Chase | 6,762,744 | 0.58% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 1,164,426,972 shares outstanding, as reported by Teva Pharmaceutical Industries Limited on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Teva Pharmaceutical Industries Limited's shareholder meeting held May 28, 2026, in the 2025-2026 proxy season, 620 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,860 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE… — Teva Pharmaceutical Industries Limited's filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Teva Pharmaceutical Industries Limited's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Teva Pharmaceutical Industries Limited’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Teva Pharmaceutical Industries Limited proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Teva Pharmaceutical Industries (TEVA) 2026 Annual Meeting”, https://proxyvotesnow.com/company/teva-pharmaceutical-industries-ltd/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.